BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rezivertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rezivertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06955325-2234@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Rezivertinib: Phase 3 readout est. (NCT06955325)
DESCRIPTION:Rezivertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Um
 brella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA
 -IB NSCLC: Focus on Driver Mutations\nEstimated primary completion: Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezivertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 55325
URL:https://assetmemo.bio/drug/rezivertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
